Related Experiment Video

Updated: Jun 29, 2026

Precise Visualization of Insulin Receptors A and B in Murine Brain with an RNA In Situ Hybridization Assay
08:34

Precise Visualization of Insulin Receptors A and B in Murine Brain with an RNA In Situ Hybridization Assay

Published on: July 15, 2025

The insulin receptor substrate-1: a biomarker for cancer?

Renato Baserga1

  • 1Thomas Jefferson University, Kimmel Cancer Center, 233 S. 10th Street, 624 BLB, Philadelphia, PA 19107, USA. r_baserga@mail.jci.tju.edu

Experimental Cell Research
|October 15, 2008
PubMed

Insights

Insulin receptor substrate-1 (IRS-1) is a potential biomarker for cancers targeted by IGF-IR. This review suggests IRS-1 may act as an anti-tumor suppressor protein, playing a broader role in cancer development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Insulin receptor substrate-1 (IRS-1) is a key signaling molecule downstream of the insulin-like growth factor 1 receptor (IGF-IR).
  • Aberrant signaling through the IGF-IR pathway is implicated in various human cancers.
  • The precise role of IRS-1 in cancer cell transformation requires further elucidation.

Purpose of the Study:

  • To review the existing literature on the role of IRS-1 in cancer cell transformation.
  • To evaluate IRS-1 as a potential biomarker for cancers responsive to IGF-IR targeted therapies.
  • To propose a novel hypothesis regarding IRS-1's function in oncogenesis.

Main Methods:

  • Comprehensive literature search and review of studies investigating IRS-1.
  • Analysis of evidence linking IRS-1 to cell transformation and cancer.
  • Synthesis of findings to support or refute IRS-1's role as a biomarker and its proposed function.

Main Results:

  • The literature provides strong evidence for IRS-1's involvement in cell transformation.
  • IRS-1 is a promising biomarker for cancers susceptible to IGF-IR targeting.
  • Emerging data suggests IRS-1 may function analogously to an anti-tumor suppressor protein.

Conclusions:

  • IRS-1 is a significant factor in cancer cell transformation.
  • IRS-1 warrants consideration as a biomarker for IGF-IR-targeted cancer therapies.
  • IRS-1 may represent a novel class of oncoproteins, acting as an 'anti-p53' molecule in cancer.

More Related Videos

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Related Concept Videos

Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: